Log in

NASDAQ:ALDRAlder Biopharmaceuticals Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$18.88
0.00 (0.00 %)
(As of 10/22/2019)
Add
Compare
Today's Range
$18.88
Now: $18.88
$18.88
50-Day Range
$18.88
MA: $18.88
$18.88
52-Week Range
$8.39
Now: $18.88
$19.12
VolumeN/A
Average Volume5.12 million shs
Market Capitalization$1.58 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.64
Alder BioPharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. The company's lead product candidate is eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine. It also develops ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 for migraine prevention; and Clazakizumab, a mAb inhibiting the pro-inflammatory cytokine interleukin-6 that has completed two Phase 2b clinical trials. The company has strategic collaboration with CSL Limited for the development of clazakizumab as a therapeutic option for solid organ transplant rejection. Alder BioPharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Bothell, Washington.
Read More
Alder Biopharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.87 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALDR
CUSIPN/A
Phone425-205-2900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.62 million
Book Value$1.61 per share

Profitability

Net Income$-296,430,000.00

Miscellaneous

Employees202
Market Cap$1.58 billion
Next Earnings DateN/A
OptionableOptionable

Receive ALDR News and Ratings via Email

Sign-up to receive the latest news and ratings for ALDR and its competitors with MarketBeat's FREE daily newsletter.

Alder Biopharmaceuticals (NASDAQ:ALDR) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Alder Biopharmaceuticals?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alder Biopharmaceuticals in the last year. There are currently 8 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Alder Biopharmaceuticals.

How were Alder Biopharmaceuticals' earnings last quarter?

Alder Biopharmaceuticals Inc (NASDAQ:ALDR) released its quarterly earnings results on Tuesday, August, 7th. The biopharmaceutical company reported ($1.04) EPS for the quarter, beating the Zacks' consensus estimate of ($1.05) by $0.01. View Alder Biopharmaceuticals' earnings history.

What price target have analysts set for ALDR?

8 analysts have issued 1-year price targets for Alder Biopharmaceuticals' shares. Their forecasts range from $18.00 to $20.00. On average, they anticipate Alder Biopharmaceuticals' stock price to reach $18.90 in the next twelve months. This suggests a possible upside of 0.1% from the stock's current price. View analysts' price targets for Alder Biopharmaceuticals.

Has Alder Biopharmaceuticals been receiving favorable news coverage?

Media coverage about ALDR stock has trended very negative on Tuesday, InfoTrie Sentiment reports. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Alder Biopharmaceuticals earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutAlder Biopharmaceuticals.

Who are some of Alder Biopharmaceuticals' key competitors?

What other stocks do shareholders of Alder Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alder Biopharmaceuticals investors own include NVIDIA (NVDA), AbbVie (ABBV), Celator Pharmaceuticals (CPXX), Celgene (CELG), Micron Technology (MU), Alibaba Group (BABA), Gilead Sciences (GILD), Synergy Pharmaceuticals (SGYP), Celldex Therapeutics (CLDX) and Exelixis (EXEL).

Who are Alder Biopharmaceuticals' key executives?

Alder Biopharmaceuticals' management team includes the following people:
  • Dr. John A. Latham, Co-Founder & Chief Scientific Officer (Age 59)
  • Mr. Larry K. Benedict, Principal Accounting Officer & Exec. VP (Age 58)
  • Dr. Jeffrey T. L. Smith, Managing Director of Alder Biopharmaceuticals Limited (Age 59)
  • Mr. Robert W. Azelby, Pres, CEO & Director (Age 51)
  • Mr. Carlos Campoy, Chief Financial Officer

What is Alder Biopharmaceuticals' stock symbol?

Alder Biopharmaceuticals trades on the NASDAQ under the ticker symbol "ALDR."

What is Alder Biopharmaceuticals' stock price today?

One share of ALDR stock can currently be purchased for approximately $18.88.

How big of a company is Alder Biopharmaceuticals?

Alder Biopharmaceuticals has a market capitalization of $1.58 billion and generates $1.62 million in revenue each year. The biopharmaceutical company earns $-296,430,000.00 in net income (profit) each year or ($4.87) on an earnings per share basis. Alder Biopharmaceuticals employs 202 workers across the globe.

What is Alder Biopharmaceuticals' official website?

The official website for Alder Biopharmaceuticals is www.alderbio.com.

How can I contact Alder Biopharmaceuticals?

Alder Biopharmaceuticals' mailing address is 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA, 98011. The biopharmaceutical company can be reached via phone at 425-205-2900 or via email at [email protected]

This page was last updated on 5/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.